Menu Search
Equities

Ascentage Pharma Group International

  • Add to watchlist
  • Add to portfolio
  • Add an alert
36X:STU

Ascentage Pharma Group International

Actions
  • Price (EUR)4.96
  • Today's Change-0.04 / -0.80%
  • Shares traded0.00
  • 1 Year change+10.22%
  • Beta0.9821
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.

  • Revenue in HKD (TTM)439.93m
  • Net income in HKD-1.31bn
  • Incorporated2017
  • Employees605.00
  • Location
    Ascentage Pharma Group International68 Xinqing Road, Suzhou Industrial ParkSuzhou ChinaCHN
  • Websitehttps://www.ascentage.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.